NEW YORK, Jan. 9, 2014 /PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the Board of Directors of United Therapeutics Corporation ("United Therapeutics" or the "Company") (Nasdaq: UTHR) concerning possible breaches of fiduciary duty and other violations of law.
The investigation concerns actions by United Therapeutics' Board of Directors that have caused the Company to allegedly engage in improper marketing tactics with regard to its three main drugs, Remodulin, Tyvaso, and Adcirca. The alleged actions are currently the subject of an investigation by the Office of the Inspector General (OIG) of the Department of Health and Human Services (HHS). Shareholders interested in seeking to recover damages on behalf of United Therapeutics and to implement corporate governance measures designed to prevent future misconduct should contact the firm.
Request more information now by clicking here: www.faruqilaw.com/UTHR
Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation. The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.
If you hold UTHR shares and you would like to discuss your legal rights, visit www.faruqilaw.com/UTHR. You can also contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to firstname.lastname@example.org.
Faruqi & Faruqi, LLP
Michael J. Hynes, Esq.
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Telephone: (877) 247-4292 or (215) 277-5770
Attorney Advertising. (C) 2014 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP